financetom
Business
financetom
/
Business
/
Air Transport Services Group Agrees to $3.1 Billion Buyout by Investment Firm Stonepeak
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Air Transport Services Group Agrees to $3.1 Billion Buyout by Investment Firm Stonepeak
Nov 4, 2024 12:10 PM

02:58 PM EST, 11/04/2024 (MT Newswires) -- Air Transport Services Group ( ATSG ) agreed to be acquired and taken private by investment firm Stonepeak in a deal valued at $3.1 billion.

The cash consideration of $22.50 per share represents a premium of about 29% over Air Transport's closing share price on Nov. 1. Shares of the aircraft lessor's were up more than 26% intraday.

"The agreement with Stonepeak will deliver immediate and certain cash value to (Air Transport Services Group's ( ATSG )) shareholders at a substantial premium to recent market prices," Joe Hete, executive chairman of Air Transport's board, said in a statement.

The transaction reflects the value of the company's in-demand midsize freighter and passenger aircraft fleet while positioning the company to further expand its global presence in the air cargo leasing market, Air Transport Services Group ( ATSG ) Chief Executive Mike Berger said.

The deal is expected to close in the first half of 2025, pending approvals by regulators and Air Transport Services Group's ( ATSG ) shareholders. At that time, the company will be delisted from the Nasdaq.

"(Air Transport Services Group's ( ATSG )) deep relationships with some of the world's largest e-commerce companies and integrators, combined with the scale and capacity of their fleet and relentless focus on safety and on-time performance, gives us confidence in the company's trajectory as a sector leader," said James Wyper, head of transportation and logistics, at Stonepeak.

In August, Air Transport Services Group ( ATSG ) reported second-quarter revenue of $488.4 million, down from $529.3 million a year earlier, while adjusted per-share earnings declined to $0.19 from $0.57.

The company is expected to report fiscal third-quarter results on Friday.

Price: 22.02, Change: +4.62, Percent Change: +26.52

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Max Power Mining Secures BLM Permits For Phase 2 Drilling at Willcox Lithium Project
Max Power Mining Secures BLM Permits For Phase 2 Drilling at Willcox Lithium Project
Mar 22, 2024
10:13 AM EDT, 03/22/2024 (MT Newswires) -- Max Power Mining Corp. ( MAXXF ) said Friday that it has secured permits from the Bureau of Land Management for phase 2 drilling at Willcox Lithium Project. The company said initial assays are expected shortly from first-ever diamond drilling at the Willcox Playa in southeast Arizona with MAX Power having completed a...
Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials
Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials
Mar 22, 2024
10:08 AM EDT, 03/22/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Friday clinical trials of its investigational drug candidate ivonescimab, alone or combined with chemotherapy, led to intercranial responses among 34% of patients with brain metasteses at baseline, with 23% seeing a complete response, in its treatment for metastatic non-small cell lung cancer. The biopharmaceutical company reported the...
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan
Mar 22, 2024
10:10 AM EDT, 03/22/2024 (MT Newswires) -- Belite Bio ( BLTE ) said Friday that it has completed the submission to Japan's Pharmaceuticals and Medical Devices Agency to start a clinical trial of its Tinlarebant product candidate in patients with Stargardt Disease. The company said the planned trial is a combination of a phase 1b study to evaluate the pharmacokinetics...
--Digital World Acquisition Gains Ahead of Shareholder Meeting to Vote on Merger With Trump Media & Technology Group
--Digital World Acquisition Gains Ahead of Shareholder Meeting to Vote on Merger With Trump Media & Technology Group
Mar 22, 2024
10:10 AM EDT, 03/22/2024 (MT Newswires) -- Price: 45.89, Change: +3.08, Percent Change: +7.19 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved